Abivax shares decline amid market weakness despite positive outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 08 Jan 26
Source: Benzinga
Abivax SA shares fell by 8.59% and hit a 5-day low amid a broader market decline, with the Nasdaq-100 down 0.59% and the S&P 500 down 0.08%.
This decline occurs despite BTIG raising the price target for Abivax SA to $150 and maintaining a Buy rating, reflecting confidence in the company's future growth potential. Additionally, Abivax outlined significant market opportunities for its lead candidate, Obefazimod, with key data readouts expected in 2026, indicating a positive long-term outlook.
The market's overall weakness suggests sector rotation, as investors may be reallocating their portfolios in response to broader market trends.
Analyst Views on ABVX
Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is 153.88 USD with a low forecast of 131.00 USD and a high forecast of 176.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 113.980
Low
131.00
Averages
153.88
High
176.00
Current: 113.980
Low
131.00
Averages
153.88
High
176.00
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
